Fund Faculdade Regional Med Sao Jose Rio Preto

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials

Phase

• Phase 11 trial
• Phase 21 trial
• Phase 31 trial

Status

• Active, not recruiting3 trials

Lead sponsor

• Amgen3 trials

Running trials

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Active, not recruiting

  Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

  NCT06333951· Phase 1· Amgen· Source